ReviewJournal of medical case reports2026
Venetoclax-based therapy in high-risk patients with relapsed/refractory multiple myeloma harboring t(11;14): a case report and review of the literature.
Review in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionMultiple myeloma is a malignant plasma cell proliferative disease that is still incurable. Individualized targeted precision therapy is the key to prolonging survival. Patients with multiple myeloma are highly heterogeneous, and patients with high-risk factors have a short median survival and poor prognosis. T(11;14) is the most common immunoglobulin heavy-chain translocation in multiple myeloma. Although it is still classified as a standard prognostic risk stratification factor based on cytogenetics, such patients have special cell biological behaviors, and the efficacy and prognosis of some patients with high-risk cytogenetics are worse than those of other standard-risk patients. Venetoclax is a highly selective oral BCL-2 inhibitor that shows good antitumor activity in relapsed and refractory multiple myeloma with t(11;14). CASE: A 71-year-old Asian female was diagnosed with relapsed and refractory multiple myeloma combined with t(11; 14); she was treated with VenDd (venetoclax + daratumumab + dexamethasone) after first-line treatment progressed. The patient achieved stringent complete response efficacy during second-line treatment, and bone marrow flow cytometry minimal residual disease continued to turn negative (10
conclusionVenetoclax combination regimen achieved excellent efficacy and safety in the treatment of relapsed/refractory multiple myeloma with t(11;14) in this case. The treatment of patients with relapsed and refractory multiple myeloma with t(11;14) by venetoclax still needs to be confirmed by more clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.